Novel approaches to the pharmacotherapy of schizophrenia

Keyphrases

• Pharmacotherapy 100%
• Schizophrenia 100%
• Schizophrenic Patients 66%
• Clinical Trials 33%
• High Dose 33%
• Tyrosine Hydroxylase 33%
• Tryptophan 33%
• Calcium Channel 33%
• Per Se 33%
• Atypical Neuroleptics 33%
• Clozapine 33%
• Extrapyramidal Side Effects 33%
• Experimental Drugs 33%
• Dyskinesia 33%
• Clinical Approach 33%
• Lithium 33%
• Drug Treatment 33%
• Calcium Channel Blockers 33%
• Benzodiazepines 33%
• Negative Symptoms 33%
• Etiological Factors 33%
• Beta-adrenergic Blockers 33%
• Prolonged Use 33%
• Vasopressin 33%
• Clonidine 33%
• Melperone 33%
• Opioid Agonist 33%
• Carbamazepine 33%
• Dopamine Autoreceptor 33%
• Fenfluramine 33%
• Comparison with a Standard 33%
• TRH Analogues 33%
• Hydroxylase Inhibitor 33%
• Opioid Antagonist 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacotherapy 100%
• Antipsychotic 100%
• Atypical Antipsychotics 25%
• Clinical Trial 25%
• 4 Aminobutyric Acid 25%
• Etiology 25%
• Tyrosine 3 Monooxygenase 25%
• Clozapine 25%
• Calcium Channel 25%
• Extrapyramidal Symptoms 25%
• Beta Adrenergic Receptor Blocking Agent 25%
• Negative Syndrome 25%
• Calcium Channel Blocker 25%
• Clonidine 25%
• Melperone 25%
• Carbamazepine 25%
• Dopamine Autoreceptor 25%
• Opiate Agonist 25%
• Protirelin Derivative 25%
• Disease 25%
• Typical Antipsychotic 25%
• Tryptophan 25%
• Dyskinesia 25%
• Fenfluramine 25%
• Vasopressin 25%
• Narcotic Antagonist 25%